Moderna, Inc.
MRNAPharma & biotechmodernatx.com
Latest available resultsJune 30, 2026Quarter · 10-Q filed Jul 31, 2026
Results announcedNovember 6, 2026EPS vs forecast ▲ +1.656 $/shareDetailed filing pending
Next reportFebruary 11, 2027after close · forecast -1.817 $/share
Revenue
$145.00M
▲ +2.1% vs prior year YoY
Net income
−$782.00M
▲ +5.2% vs prior year YoY
EPS
-1.97$
▲ +7.5% vs prior year YoY
Net margin
-539.3%
▲ +41.7 pp vs prior year YoY
Revenue▲ +2.1%
Margins (% of revenue)GrossOperatingNet
Net income▲ +5.2%
EPS▲ +7.5%
Financial statements
View 10-Q filed July 31, 2026 on SEC ↗| Metric | Sep 2024 | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $1.86B | $966.00M | $108.00M | $142.00M | $1.02B | $678.00M | $389.00M | $145.00M | ▲ +2.1% |
| Gross profit | $1.35B | $227.00M | $18.00M | $23.00M | $809.00M | $226.00M | — | $52.00M | ▲ +126.1% |
| Operating income | −$70.00M | −$1.25B | −$1.05B | −$907.00M | −$260.00M | −$857.00M | −$1.39B | −$815.00M | ▲ +10.1% |
| Net income | $13.00M | −$1.12B | −$971.00M | −$825.00M | −$200.00M | −$826.00M | −$1.34B | −$782.00M | ▲ +5.2% |
| R&D | $1.14B | $1.12B | $856.00M | $700.00M | $801.00M | $775.00M | $649.00M | $651.00M | ▼ -7.0% |
| EPS (diluted) | 0.03 $ | — | -2.52 $ | -2.13 $ | -0.51 $ | — | -3.40 $ | -1.97 $ | ▲ +7.5% |
| Margins (% of revenue) | |||||||||
| Gross | 72.4 % | 23.5 % | 16.7 % | 16.2 % | 79.6 % | 33.3 % | — | 35.9 % | ▲ +19.7 pt |
| Operating | -3.8 % | -129.0 % | -972.2 % | -638.7 % | -25.6 % | -126.4 % | -356.8 % | -562.1 % | ▲ +76.7 pt |
| Net | 0.7 % | -115.9 % | -899.1 % | -581.0 % | -19.7 % | -121.8 % | -345.2 % | -539.3 % | ▲ +41.7 pt |
| Balance sheet | |||||||||
| Assets | $15.80B | $14.14B | $12.70B | $12.01B | $12.13B | $12.34B | $11.49B | $10.96B | ▼ -8.7% |
| Liabilities | $3.88B | $3.24B | $2.64B | $2.61B | $2.81B | $3.69B | $4.08B | $4.20B | ▲ +60.9% |
| Equity | $11.93B | $10.90B | $10.07B | $9.40B | $9.33B | $8.65B | $7.41B | $6.76B | ▼ -28.1% |
| Cash | $1.64B | $1.93B | $1.62B | $1.28B | $1.13B | $2.60B | $1.91B | $1.72B | ▲ +34.7% |
| Capital | |||||||||
| Shares outstanding | 384.82M | 385.82M | 386.74M | 389.08M | 390.68M | 394.94M | 396.79M | 399.24M | ▲ +2.6% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.